What to know about Berkshire's $9.7 billion deal to buy OxyChem, Buffett’s biggest deal since 2022

Joining us this morning to break it all down is Roth Capital Partners senior research analyst Leo Mariani. Has a neutral rating and a 46 target on Oxy. Uh Lou L, good to have you.Um been in the works for seems a while here. We've been learning about it via reports for the past several days. Implications for Oxy and and overall uh concerns about debt load.Yeah. Yeah. So, I think that was one of the the key reasons they pulled the trigger on the transaction here is that amongst the the larger EMP companies in ...